Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Chief Scientific Officer +41 22 534 94 80
contact@axalbion.com


Chief Medical Officer +41 22 534 94 80
contact@axalbion.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Efficacy and Safety of AX-8 in Chronic Cough

A Study of Efficacy and Safety of AX-8 in Chronic Cough

Medical Conditions

Cough
Chronic Cough


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8 in participants with unexplained or refractory chronic cough designed to evaluate the effectiveness of AX-8 in reducing cough frequency.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2021 May 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : orally disintegrating tablets, BID

Intervention Arm Group : AX-8 to Placebo, Part 1 of the study;Placebo to AX-8, Part 1 of the study;

Intervention Type : DRUG
Intervention Description : orally disintegrating tablets, BID

Intervention Arm Group : AX-8 to Placebo, Part 1 of the study;Placebo to AX-8, Part 1 of the study;

Intervention Type : DRUG
Intervention Description : orally disintegrating tablets, TID

Intervention Arm Group : AX-8 to Placebo, Part 2 of the study;Placebo to AX-8, Part 2 of the study;

Intervention Type : DRUG
Intervention Description : orally disintegrating tablets, TID

Intervention Arm Group : AX-8 to Placebo, Part 2 of the study;Placebo to AX-8, Part 2 of the study;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Axalbion Study Site 4406
    Birmingham
    England
    B9 5SS
  • Axalbion Study Site 4404
    Broughton
    England
    DN20 0HR
  • Axalbion Study Site 4409
    Chelmsford
    England
    CM1 7ET
  • Axalbion Study Site 4413
    Coventry
    England
    CV3 4FJ
  • Axalbion Study Site 4401
    London
    England
    SE5 9RS
  • Axalbion Study Site 4402
    London
    England
    SW3 6HP
  • Axalbion Study Site 4410
    London
    England
    W2 1NY
  • Axalbion Study Site 4403
    Manchester
    England
    M23 9LT
  • Axalbion Study Site 4405
    North Shields
    England
    NE29 8NH
  • Axalbion Study Site 4407
    Oxford
    England
    OX3 9DU
  • Axalbion Study Site 4411
    Preston
    England
    PR2 9HT
  • Axalbion Study Site 4412
    Shipley
    England
    BD18 3SA
  • Axalbion Study Site 4408
    Newport
    Wales
    NP20 2EF
  • Axalbion Study Site 4414
    Belfast
    BT9 7AB
  • Axalbion Study Site 4415
    Northwood
    HA6 2RN
  • Axalbion Study Site 4417
    Orpington
    England
    BR5 3QG

Chief Scientific Officer +41 22 534 94 80
contact@axalbion.com


Chief Medical Officer +41 22 534 94 80
contact@axalbion.com



The study is sponsored by Axalbion SA




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT04866563
Last updated 27 January 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.